IQVIA HOLDINGS INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $557.00M, a 29.84% increase year-over-year.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for the quarter ending 2025-06-30 was $613.00M.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for the quarter ending 2025-03-31 was $429.00M.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for the quarter ending 2024-09-30 was $200.00M, a 37.93% increase year-over-year.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for fiscal 2025 was $1.25B, a 7.93% decline from fiscal 2024.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for fiscal 2024 was $1.36B, a 36.06% increase from fiscal 2023.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for fiscal 2023 was $1.00B, a 14.30% decline from fiscal 2022.
- IQVIA HOLDINGS INC. treasury stock, value, acquired, cost method for fiscal 2022 was $1.17B, a 187.68% increase from fiscal 2021.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-03-31 | $557.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.25B 10-K · filed 2026-02-17 | |
| 2025-06-30 | $613.00M 10-Q · filed 2025-10-28 | |
| 2025-03-31 | $429.00M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $1.36B 10-K · filed 2026-02-17 | |
| 2024-09-30 | $200.00M 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $1.00B 10-K · filed 2026-02-17 | |
| 2023-09-30 | $145.00M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $495.00M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $129.00M 10-Q · filed 2024-10-31 | |
| 2022-12-31 | $1.17B 10-K · filed 2025-02-13 | |
| 2022-09-30 | $129.00M 10-Q · filed 2024-05-02 | |
| 2022-06-30 | $590.00M 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $403.00M 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $406.00M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $125.00M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $45.00M 10-Q · filed 2022-10-27 | |
| 2021-03-31 | $62.00M 10-Q · filed 2022-10-27 | |
| 2020-12-31 | $433.00M 10-K · filed 2023-02-15 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-07-28 | |
| 2020-03-31 | $332.00M 10-Q · filed 2021-10-22 | |
| 2019-12-31 | $963.00M 10-K · filed 2022-02-16 | |
| 2019-09-30 | $313.00M 10-Q · filed 2020-10-22 | $1.30B derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-06-30 | $236.00M 10-Q · filed 2020-10-22 | $1.12B derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-03-31 | $145.00M 10-Q · filed 2020-10-22 | $1.46B derived: sum of 4 quarters · filed 2021-02-12 |
| 2018-12-31 | $604.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $1.40B 10-K · filed 2021-02-12 |
| 2018-09-30 | $134.00M 10-Q · filed 2019-11-01 | |
| 2018-06-30 | $573.00M 10-Q · filed 2019-11-01 | |
| 2018-03-31 | $86.00M 10-Q · filed 2019-11-01 | |
| 2017-12-31 | $2.37B 10-K · filed 2020-02-18 | |
| 2016-12-31 | $1.00B 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |